Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy

Bone Marrow Transplantation

Volumn 20, Issue 2, 1997, Pages 167-169

  Pedrazzoli, P ^a   Battaglia, M ^a   Da Prada, G A ^a   Lanza, A ^a   Cuomo, A ^a   Bertolini, F ^a   Pavesi, L ^a   Robustelli Della Cuna, G ^a  

^a IRCCS   (Italy)

Author keywords

Metastatic breast cancer; PBPC transplantation; Tumor recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CANCER RECURRENCE; CASE REPORT; CONTAMINATION; DRUG MEGADOSE; FEMALE; HUMAN; LEUKAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TUMOR CELL;

EID: 0030738038     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700854     Document Type: Article

References (15)

1. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. In: De Vita VT, Hellman S, Rosemberg SA (eds). Important Advances in Oncology. JB Lippincott: Philadelphia, 1995, p 215.
2. Osborne MP. Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994; 8: 25-31.
3. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
4. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
5. Deisserot AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation. Blood 1994; 83: 3068-3076.
6. Kasper M, Stosiek K, Typlt H et al. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1 Normal tissues. Eur J Cancer 1987; 23: 137-147.
7. Kruger W, Krzizanowski C, Holweg M et al. Reverse transcriptase polymerase chain reaction detection of cytokeratin 19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996; 122: 679-686.
8. Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337-344.
9. Tyer CL, Vredenburg JJ, Heimer M et al. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 1996; 2: 81-86.
10. Koenigsmann MP, Notter M, Knauf WU et al. Chemopurging of peripheral blood-derived progenitor cells by alkyllysophospholipid and its effect on haematopoietic rescue after high-dose chemotherapy. Bone Marrow Transplant 1996; 18: 549-557.
11. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
12. Kessinger A, Reed E, Aughan W et al. Clinical outcome of patients (pts) with breast cancer and gynecological epithelial tumors undergoing high-dose therapy and peripheral stem cell transplantation with or without minimally contaminated apheresis harvests. Proc Am Soc Clin Oncol 1993; 12: A97.
13. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
14. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
15. Rizzoli V, Carlo Stella C. Stem cell purging: an intriguing dilemma. Exp Hematol 1995; 23: 296-302.